BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06132256 (axatilimab in idiopathic pulmonary fibrosis): BVCT ex-ante prediction vs. reported outcome

On 30 Nov 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 12 Oct 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06132256
Acronym
MAXPIRe
Drug Name
axatilimab
Drug MoA
CSF1R inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Respiratory Tract Diseases
Indication
idiopathic pulmonary fibrosis
Human Patients
145
Sponsor
Syndax Pharmaceuticals
Phase
Phase 2

Prediction of , index 1354

Prospective Prediction
Prediction Index
1354
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
1047 days in advance
Readout Data Interpretation
axatilimab failed to met the primary endpoint in FVC improvement at week 26; further development discontinued.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase
Phase 2
Status
Active not recruiting
Enrollment
145
Lead sponsor
Syndax Pharmaceuticals
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG: Axatilimab; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-12-11
Primary completion
2026-09
Completion
2026-11
Primary outcomes
  • Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL]) (Baseline through Week 26)

NCT06132256 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials